Compare ADMA Biologics Inc (ADMA) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while GraniteShares 2x Long NVDA Daily ETF trades at $30.09. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NVDL | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $43.02 |
52-Week Low | $7.60 | $21.76 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $28.53 with a 1.1% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF has demonstrated significant volatility, with a 12% single-day drop in early June 2026 highlighting the risks of daily leverage reset. Recent stock splits (1:3 on June 25-26, 2026) have adjusted share structure.
The outlook for NVDL remains tied to NVIDIA's performance and AI sector momentum. While the ETF offers leveraged exposure to NVDA's gains, it carries substantial risk from daily rebalancing during market downturns. Investors should weigh the potential for amplified returns against the documented volatility and structural risks of leveraged ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
